Cellfina

What Cellfina does

Cellfina is an FDA-cleared medical device system marketed for the long-term improvement of cellulite appearance (dimpled skin on the buttocks and thighs). Its underlying mechanism is vacuum-assisted precision subcision: a small needle-sized blade is guided under local anesthesia to release the fibrous septae that tether skin and produce cellulite dimples, treating the structural cause rather than applying surface-level therapy.

Cellfina is owned and commercialized by Merz North America, Inc. (operating as Merz Aesthetics), headquartered at 6500 Six Forks Road, Raleigh, North Carolina. The parent, with over 115 years of aesthetics heritage dating to its 1908 founding, integrates Cellfina within a portfolio that also includes injectable brands and other aesthetic devices. Distribution is executed through Merz Aesthetics' dedicated U.S. field sales network selling into dermatology and plastic surgery practices; pricing is built around a capital equipment purchase coupled with per-procedure consumables, positioning Cellfina as a premium, in-office treatment rather than a consumer retail product.

Cellfina's customer base is the practicing aesthetic clinician — dermatologists, plastic surgeons, and medical spas with physician oversight — rather than end consumers. No direct revenue disclosure, employee count specific to the brand, or unit shipment data is available in the supplied source material; available signals describe the device's mechanism, regulatory clearance, and the parent's broader commercial positioning at events such as IMCAS World Congress 2026.

Name

Cellfina

Legal name

Merz North America, Inc.

Website

https://cellfina.com

Company type

Private

Founded year

1908

Operating status

Operating

Headcount range

1–10 employees

Short description

Cellfina is an FDA-cleared, vacuum-assisted precision subcision medical device for long-term improvement of cellulite, owned and sold by Merz Aesthetics to dermatology, plastic surgery, and medical spa practices through a U.S. field sales network.

Ownership category

akta.pro rank

Product category

Aesthetic Medical Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Microneedling / Collagen Induction Therapy (HSALADAI)

Keywords

• Minimally invasive aesthetics
• Cellulite treatment device
• Subcision medical device
• FDA-cleared dermatology equipment
• Body contouring system

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Operations, Personnel

Revenue model

1. Medical Device Sales: Sale of Cellfina treatment systems and consumables to aesthetic clinics and healthcare providers who perform the procedures on patients seeking treatment for dimpled skin and body contouring.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Cellfina is a vacuum-assisted precision device system that performs minimally invasive subcision to release the fibrous septae bands beneath the skin that cause dimpled skin (cellulite). The system is FDA-cleared and sold to physicians and aesthetic practices as an in-office procedure platform for the long-term improvement of cellulite appearance on the buttocks and thighs.

Product overview

Merz Aesthetics offers a product portfolio tailored to a wide variety of aesthetic goals. The primary product identified in available sources is RADIESSE®, a dermal filler used for wrinkle treatment and aesthetic enhancements. The company operates the Merz Aesthetics Exchange (MAX) platform for customer engagement and learning, and the Merz Aesthetics Portal for US customer access. The portfolio appears to focus on aesthetic medical devices and injectable treatments with over 115 years of proven results.

Differentiator

Problem solved

Functional benefit

Products and services

• Cellfina System Vacuum-assisted precision device system that performs subcision to release the fibrous septae bands beneath the skin that cause dimpled skin (cellulite). It is sold to licensed physicians and aesthetic practices as an in-office treatment platform.

Segments2 records

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves3 records

Expansion highlights2 records

Direct peers

• Cynosure: Aesthetic and medical device company offering energy-based platforms for body contouring, skin revitalization, and women's health. Overlaps with Cellfina in the clinic-channel aesthetic device market served to dermatologists and plastic surgeons.
• InMode: Aesthetic and medical device company with body contouring, skin tightening, and resurfacing platforms (Morpheus8, BodyTite). Directly comparable clinic-channel device competitor addressing body and skin aesthetics.
• Endo Aesthetics: Markets Qwo, the first FDA-approved injectable treatment for moderate-to-severe cellulite in the buttocks of adult women. Directly comparable to Cellfina as a competing FDA-cleared modality for the same structural cellulite indication.
• Alma Lasers: Global aesthetic and medical laser company offering body contouring, skin rejuvenation, and women's health platforms. Comparable clinic-channel device peer with overlapping body and skin aesthetic indications.
• Cutera: Aesthetic device company offering laser- and energy-based platforms for body contouring, skin revitalization, and hair removal. Comparable clinic-channel device peer for body and skin aesthetics.
• Venus Concept: Markets non-invasive aesthetic devices for body contouring, skin tightening, and facial rejuvenation sold to clinics and medspas. Comparable as a clinic-channel aesthetic device peer addressing overlapping indications.
• BTL Aesthetics: Markets non-invasive body contouring and muscle-stimulating devices (EmSculpt) sold to aesthetic clinics. Competes with Cellfina for the same body-contouring patient demand via a non-invasive modality.
• Solta Medical: Aesthetic device business (Thermage, Fraxel, Clear+Brilliant) sold into dermatology and plastic surgery channels. Comparable as a clinic-channel aesthetic device portfolio targeting body and skin concerns alongside Cellfina.

Broad incumbents

• Galderma: Global dermatology and aesthetics company with injectables, skincare, and therapeutic dermatology. Comparable as a broad incumbent operating across clinic-channel aesthetic categories adjacent to Cellfina.
• Allergan Aesthetics (AbbVie): Large aesthetics portfolio including CoolSculpting for non-invasive fat reduction and the broader Botox/ filler franchise. Overlaps with Cellfina as a broader incumbent in body contouring and clinic-channel aesthetics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@merzestheticsglobal
• Facebookfacebook.com/Cellfina
• LinkedInlinkedin.com/company/merz-aesthetics-inc.
• Instagraminstagram.com/merzesthetics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellfina